+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Irritable Bowel Syndrome - Pipeline Review, H2 2019

  • ID: 4894133
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 162 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • 4D Pharma Plc
  • Axim Biotechnologies Inc
  • Dong-A ST Co Ltd
  • GEXVal Inc
  • Metacrine Inc
  • Orphomed Inc
  • MORE
Irritable Bowel Syndrome - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Irritable Bowel Syndrome - Pipeline Review, H2 2019, provides an overview of the Irritable Bowel Syndrome (Gastrointestinal) pipeline landscape.

Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder that affects large intestine (colon). Symptoms include cramping, abdominal pain, bloating gas, diarrhea, backache, muscle pains, poor appetite and constipation. These symptoms can be triggered by food, stress and hormones. Risk factors include age and family history. Treatment includes anti-diarrheal, anticholinergic, antidepressant and antibiotics medications.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Irritable Bowel Syndrome - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Irritable Bowel Syndrome (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Irritable Bowel Syndrome (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Irritable Bowel Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 11, 6, 1, 10, 9 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Irritable Bowel Syndrome (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Irritable Bowel Syndrome (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Irritable Bowel Syndrome (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Irritable Bowel Syndrome (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Irritable Bowel Syndrome (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Irritable Bowel Syndrome (Gastrointestinal)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Irritable Bowel Syndrome (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Irritable Bowel Syndrome (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • 4D Pharma Plc
  • Axim Biotechnologies Inc
  • Dong-A ST Co Ltd
  • GEXVal Inc
  • Metacrine Inc
  • Orphomed Inc
  • MORE
Introduction
Report Coverage
Irritable Bowel Syndrome - Overview
Irritable Bowel Syndrome - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Irritable Bowel Syndrome - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Irritable Bowel Syndrome - Companies Involved in Therapeutics Development
4D Pharma Plc
Allergan Plc
Ardelyx Inc
AsiaBiome
Axim Biotechnologies Inc
Bausch Health Companies Inc
Biomica
Boston Pharmaceuticals Inc
CinRx Pharma LLC
ConSynance Therapeutics Inc
Cosmo Pharmaceuticals NV
Dong-A ST Co Ltd
Eisai Co Ltd
Enterome Bioscience SA
Exeliom Biosciences SAS
GEXVal Inc
ImmuneBiotech AB
Ironwood Pharmaceuticals Inc
Jiangsu Aosaikang Pharmaceutical Co Ltd
LTT Bio-Pharma Co Ltd
Merck & Co Inc
Metacrine Inc
MGC Pharmaceuticals Ltd
Napo Pharmaceuticals Inc
Novome Biotechnologies Inc
Oncocross Co Ltd
Orphomed Inc
Outpost Medicine Ltd
Protagonist Therapeutics Inc
RaQualia Pharma Inc
RedHill Biopharma Ltd
Renexxion LLC
Sentia Medical Sciences Inc
Serentrix LLC
Synthetic Biologics Inc
Velicept Therapeutics Inc
Vitality Biopharma Inc
Irritable Bowel Syndrome - Drug Profiles
AB-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologic for Irritable Bowel Syndrome with Constipation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologic for Irritable Bowel Syndrome with Diarrhea - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologics for Irritable Bowel Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMC-426 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BOS-589 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Canchew Plus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cannabidiol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CIN-103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
crofelemer DR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CSTI-300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DA-6886 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs for Inflammation and Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
E-2508 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EB-410 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EB-420 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GXV-004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IB-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
linaclotide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lovastatin MR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LT-4006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MET-409 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MRx-1234 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naronapride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NBX-1650 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OC-211 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ondansetron hydrochloride CR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OP-687 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ORP-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
plecanatide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PR-38 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Ramosetron Hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rifamycin sodium CR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RQ-00310941 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SER-224 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit TPH1 for Gastrointestinal, Metabolic Disorder and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
solabegron - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Agonize DOR1 and MOR1 for Irritable Bowel Syndome with Diarrhea - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Antagonize CRHR1 and CRHR2 for Gastrointestinal Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tenapanor hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VB-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VB-210 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vibegron - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Irritable Bowel Syndrome - Dormant Projects
Irritable Bowel Syndrome - Discontinued Products
Irritable Bowel Syndrome - Product Development Milestones
Featured News & Press Releases
Oct 28, 2019: Salix Pharmaceuticals to present new clinical data on TRULANCE (Plecanatide) at the American College of Gastroenterology (ACG) Annual Meeting
Oct 18, 2019: Cipher Pharmaceuticals receives Health Canada approval For Trulance (Plecanatide)
Sep 26, 2019: Synthetic Biologics strengthens U.S. patent coverage of SYN-010, intended for the novel treatment of irritable bowel syndrome with constipation (IBS-C)
Sep 12, 2019: Ardelyx receives FDA Approval for IBSRELA (Tenapanor), an NHE3 Sodium Transport Inhibitor, for the treatment of Irritable Bowel Syndrome with Constipation
Aug 15, 2019: Alfasigma USA announces ZELNORM (tegaserod) now available for treatment of irritable bowel syndrome with constipation
Jul 22, 2019: Ironwood Pharmaceuticals Allergan provides update on its ANDA Lawsuit
Jun 26, 2019: Knight announces filing of New Drug Submission for Ibsrela in Canada
Jun 20, 2019: Ironwood and Allergan’s LINZESS trial meets primary endpoint
May 22, 2019: Sentia Medical Sciences awarded approximately $1.8 million phase II small business innovation research (SBIR) grant to develop Astressins for the treatment of irritable bowel syndrome (IBS)
May 14, 2019: Salix Pharmaceuticals presents data on TRULANCE at Digestive Disease Week
May 09, 2019: Ironwood Pharmaceuticals to highlight linaclotide data at Digestive Disease Week 2019
Apr 01, 2019: FDA approves the reintroduction of Zelnorm™ (tegaserod) for Irritable Bowel Syndrome with Constipation (IBS-C) in women under 65
Jan 18, 2019: Linzess (linaclotide) approved in China for the treatment of irritable bowel syndrome with constipation
Jan 15, 2019: Ironwood Pharmaceuticals announces approval of LINZESS (linaclotide) in China for the treatment of adults with IBS-C
Jan 07, 2019: Jaguar Health Provides Fourth Quarter 2018 Commercial Sales Updates
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Irritable Bowel Syndrome, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Irritable Bowel Syndrome - Pipeline by 4D Pharma Plc, H2 2019
Irritable Bowel Syndrome - Pipeline by Allergan Plc, H2 2019
Irritable Bowel Syndrome - Pipeline by Ardelyx Inc, H2 2019
Irritable Bowel Syndrome - Pipeline by AsiaBiome, H2 2019
Irritable Bowel Syndrome - Pipeline by Axim Biotechnologies Inc, H2 2019
Irritable Bowel Syndrome - Pipeline by Bausch Health Companies Inc, H2 2019
Irritable Bowel Syndrome - Pipeline by Biomica, H2 2019
Irritable Bowel Syndrome - Pipeline by Boston Pharmaceuticals Inc, H2 2019
Irritable Bowel Syndrome - Pipeline by CinRx Pharma LLC, H2 2019
Irritable Bowel Syndrome - Pipeline by ConSynance Therapeutics Inc, H2 2019
Irritable Bowel Syndrome - Pipeline by Cosmo Pharmaceuticals NV, H2 2019
Irritable Bowel Syndrome - Pipeline by Dong-A ST Co Ltd, H2 2019
Irritable Bowel Syndrome - Pipeline by Eisai Co Ltd, H2 2019
Irritable Bowel Syndrome - Pipeline by Enterome Bioscience SA, H2 2019
Irritable Bowel Syndrome - Pipeline by Exeliom Biosciences SAS, H2 2019
Irritable Bowel Syndrome - Pipeline by GEXVal Inc, H2 2019
Irritable Bowel Syndrome - Pipeline by ImmuneBiotech AB, H2 2019
Irritable Bowel Syndrome - Pipeline by Ironwood Pharmaceuticals Inc, H2 2019
Irritable Bowel Syndrome - Pipeline by Jiangsu Aosaikang Pharmaceutical Co Ltd, H2 2019
Irritable Bowel Syndrome - Pipeline by LTT Bio-Pharma Co Ltd, H2 2019
Irritable Bowel Syndrome - Pipeline by Merck & Co Inc, H2 2019
Irritable Bowel Syndrome - Pipeline by Metacrine Inc, H2 2019
Irritable Bowel Syndrome - Pipeline by MGC Pharmaceuticals Ltd, H2 2019
Irritable Bowel Syndrome - Pipeline by Napo Pharmaceuticals Inc, H2 2019
Irritable Bowel Syndrome - Pipeline by Novome Biotechnologies Inc, H2 2019
Irritable Bowel Syndrome - Pipeline by Oncocross Co Ltd, H2 2019
Irritable Bowel Syndrome - Pipeline by Orphomed Inc, H2 2019
Irritable Bowel Syndrome - Pipeline by Outpost Medicine Ltd, H2 2019
Irritable Bowel Syndrome - Pipeline by Protagonist Therapeutics Inc, H2 2019
Irritable Bowel Syndrome - Pipeline by RaQualia Pharma Inc, H2 2019
Irritable Bowel Syndrome - Pipeline by RedHill Biopharma Ltd, H2 2019
Irritable Bowel Syndrome - Pipeline by Renexxion LLC, H2 2019
Irritable Bowel Syndrome - Pipeline by Sentia Medical Sciences Inc, H2 2019
Irritable Bowel Syndrome - Pipeline by Serentrix LLC, H2 2019
Irritable Bowel Syndrome - Pipeline by Synthetic Biologics Inc, H2 2019
Irritable Bowel Syndrome - Pipeline by Velicept Therapeutics Inc, H2 2019
Irritable Bowel Syndrome - Pipeline by Vitality Biopharma Inc, H2 2019
Irritable Bowel Syndrome - Dormant Projects, H2 2019
Irritable Bowel Syndrome - Dormant Projects, H2 2019 (Contd..1), H2 2019
Irritable Bowel Syndrome - Dormant Projects, H2 2019 (Contd..2), H2 2019
Irritable Bowel Syndrome - Dormant Projects, H2 2019 (Contd..3), H2 2019
Irritable Bowel Syndrome - Discontinued Products, H2 2019

List of Figures
Number of Products under Development for Irritable Bowel Syndrome, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • 4D Pharma Plc
  • Allergan Plc
  • Ardelyx Inc
  • AsiaBiome
  • Axim Biotechnologies Inc
  • Bausch Health Companies Inc
  • Biomica
  • Boston Pharmaceuticals Inc
  • CinRx Pharma LLC
  • ConSynance Therapeutics Inc
  • Cosmo Pharmaceuticals NV
  • Dong-A ST Co Ltd
  • Eisai Co Ltd
  • Enterome Bioscience SA
  • Exeliom Biosciences SAS
  • GEXVal Inc
  • ImmuneBiotech AB
  • Ironwood Pharmaceuticals Inc
  • Jiangsu Aosaikang Pharmaceutical Co Ltd
  • LTT Bio-Pharma Co Ltd
  • Merck & Co Inc
  • Metacrine Inc
  • MGC Pharmaceuticals Ltd
  • Napo Pharmaceuticals Inc
  • Novome Biotechnologies Inc
  • Oncocross Co Ltd
  • Orphomed Inc
  • Outpost Medicine Ltd
  • Protagonist Therapeutics Inc
  • RaQualia Pharma Inc
  • RedHill Biopharma Ltd
  • Renexxion LLC
  • Sentia Medical Sciences Inc
  • Serentrix LLC
  • Synthetic Biologics Inc
  • Velicept Therapeutics Inc
  • Vitality Biopharma Inc
Note: Product cover images may vary from those shown
Adroll
adroll